Paper39338268
Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A "Real-Life" Observational Study.
De Corso E and 20 others. J Pers Med, 2024. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A "Real-Life" Observational Study. Papers, record 39338268. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39338268
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A "Real-Life" Observational Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29316300 | Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population. | Int Forum Allergy Rhinol | 2018 | https://conductscience.org/library/papers/29316300 | PubMed |
| 2 | 33595845 | Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial. | Clin Exp Allergy | 2021 | https://conductscience.org/library/papers/33595845 | PubMed |
| 3 | 36013200 | Sinonasal Biomarkers Defining Type 2-High and Type 2-Low Inflammation in Chronic Rhinosinusitis with Nasal Polyps. | J Pers Med | 2022 | https://conductscience.org/library/papers/36013200 | PubMed |
| 4 | 17021776 | Normative data for the "Sniffin' Sticks" including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. | Eur Arch Otorhinolaryngol | 2007 | https://conductscience.org/library/papers/17021776 | PubMed |
| 5 | 38849701 | Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan. | Drugs | 2024 | https://conductscience.org/library/papers/38849701 | PubMed |
| 6 | 32250875 | Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. | Respir Med | 2020 | https://conductscience.org/library/papers/32250875 | PubMed |
| 7 | 32816558 | Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. | Int J Immunopathol Pharmacol | 2020 | https://conductscience.org/library/papers/32816558 | PubMed |
| 8 | 27609408 | Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. | Lancet | 2016 | https://conductscience.org/library/papers/27609408 | PubMed |
| 9 | 23021878 | Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. | J Allergy Clin Immunol | 2013 | https://conductscience.org/library/papers/23021878 | PubMed |
| 10 | 38829175 | Outcome measures for chronic rhinosinusitis with nasal polyps. | Rhinology | 2024 | https://conductscience.org/library/papers/38829175 | PubMed |
| 11 | 27609406 | Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. | Lancet | 2016 | https://conductscience.org/library/papers/27609406 | PubMed |
| 12 | 36507741 | The EUFOREA pocket guide for chronic rhinosinusitis. | Rhinology | 2023 | https://conductscience.org/library/papers/36507741 | PubMed |
| 13 | 38426234 | Eosinophil extracellular traps in eosinophilic chronic rhinosinusitis induce Charcot-Leyden crystal formation and eosinophil recruitment. | Biosci Rep | 2024 | https://conductscience.org/library/papers/38426234 | PubMed |
| 14 | 30478909 | Antileukotrienes improve naso-ocular symptoms and biomarkers in patients with NARES and asthma. | Laryngoscope | 2019 | https://conductscience.org/library/papers/30478909 | PubMed |
| 15 | 39064286 | Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis. | J Clin Med | 2024 | https://conductscience.org/library/papers/39064286 | PubMed |
| 16 | 14713908 | Development of the asthma control test: a survey for assessing asthma control. | J Allergy Clin Immunol | 2004 | https://conductscience.org/library/papers/14713908 | PubMed |
| 17 | 28530840 | Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28530840 | PubMed |
| 18 | 19767070 | The minimally important difference of the Asthma Control Test. | J Allergy Clin Immunol | 2009 | https://conductscience.org/library/papers/19767070 | PubMed |
| 19 | 38266634 | Correlation between inflammatory biomarkers and disease control in chronic rhinosinusitis with nasal polyps. | Int Forum Allergy Rhinol | 2024 | https://conductscience.org/library/papers/38266634 | PubMed |
| 20 | 32499305 | Minimal clinically important difference for asthma endpoints: an expert consensus report. | Eur Respir Rev | 2020 | https://conductscience.org/library/papers/32499305 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42827160 | Real-world two-year outcomes of mepolizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting severe asthma. | Eur Arch Otorhinolaryngol | 2026 | https://conductscience.org/library/papers/42827160 | PubMed |
| 42646747 | Staphylococcus Aureus Toxins and Asthma: Pathophysiological Mechanisms, Clinical Relevance, and Therapeutic Implications in the Biologics Era. | Toxins (Basel) | 2026 | https://conductscience.org/library/papers/42646747 | PubMed |
| 42511972 | Recovery of Olfactory Function After Mepolizumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps: Influence of the Number of Surgeries. | Biomedicines | 2026 | https://conductscience.org/library/papers/42511972 | PubMed |
| 41903052 | Psychophysical Olfactory Outcomes After Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis. | Curr Allergy Asthma Rep | 2026 | https://conductscience.org/library/papers/41903052 | PubMed |
| 41608597 | Global airways: a Danish nationwide real-life registry of biologic therapy for chronic rhinosinusitis with nasal polyps. | Front Allergy | 2025 | https://conductscience.org/library/papers/41608597 | PubMed |
| 41261303 | Restoring the Sense of Smell: A Systematic Review and Meta-Analysis of Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyps. | Curr Allergy Asthma Rep | 2025 | https://conductscience.org/library/papers/41261303 | PubMed |
| 40237828 | [Diagnosis and drug therapy of chronic rhinosinusitis]. | HNO | 2025 | https://conductscience.org/library/papers/40237828 | PubMed |
| 40200389 | Benralizumab and the integrated management of co-morbid severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps. | Clin Transl Allergy | 2025 | https://conductscience.org/library/papers/40200389 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IL5RA | 3568 | PubTator's text mining | https://conductscience.org/library/genes/3568 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39338268
GET https://conductscience.org/api/papers/v1/39338268/authors?page=2